{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=29",
    "query": {
      "condition": "Cancer of the Stomach",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 951,
    "total_pages": 96,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+the+Stomach&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T08:00:37.222Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005860",
      "title": "Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "floxuridine",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-04-26",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005860"
    },
    {
      "nct_id": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 2,
      "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005842"
    },
    {
      "nct_id": "NCT02318329",
      "title": "Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Gastric Cancer",
        "Transitional Cell Carcinoma of the Bladder"
      ],
      "interventions": [
        {
          "name": "FPA144",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Five Prime Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2014-11",
      "completion_date": "2019-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02318329"
    },
    {
      "nct_id": "NCT05678205",
      "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "AB-201",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-08-01",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05678205"
    },
    {
      "nct_id": "NCT05997056",
      "title": "Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "NET",
        "Pancreatic Neuroendocrine Tumor",
        "Gastrointestinal Neuroendocrine Tumor",
        "Pulmonary Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "nab-sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aadi Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-10-20",
      "completion_date": "2025-10-03",
      "has_results": true,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 4,
      "location_summary": "Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05997056"
    },
    {
      "nct_id": "NCT03076372",
      "title": "A Study Evaluating MM-310 in Patients With Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Urothelial Carcinoma",
        "Gastric Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Ovarian Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Prostate Adenocarcinoma",
        "Non-small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Endometrial Carcinoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "MM-310",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-02-22",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03076372"
    },
    {
      "nct_id": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Melanoma",
        "Carcinoma",
        "Sarcoma",
        "Lung Cancer",
        "Prostate Cancer",
        "Breast Cancer",
        "Colo-rectal Cancer",
        "Uterine Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Thyroid Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "KVA12123 - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 Plus Pembrolizumab - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 - Dose Expansion",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 Plus Pembrolizumab - Dose Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kineta Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-03-03",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 7,
      "location_summary": "Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05708950"
    },
    {
      "nct_id": "NCT02500043",
      "title": "Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Refractory Metastatic Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "TAS-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 507,
      "start_date": "2016-02-24",
      "completion_date": "2019-12-19",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 24,
      "location_summary": "Gilbert, Arizona • Berkeley, California • Fullerton, California + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500043"
    },
    {
      "nct_id": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Cancer",
        "Cutaneous Melanoma",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AU-007",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aulos Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2022-04-04",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267626"
    },
    {
      "nct_id": "NCT00066404",
      "title": "Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant adenovirus-hIFN-beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-10-26T08:00:37.222Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066404"
    }
  ]
}